EVNIN LUKE 4
4 · Werewolf Therapeutics, Inc. · Filed May 20, 2026
Research Summary
AI-generated summary of this filing
Werewolf Therapeutics (HOWL) Director Luke Evnin Sells Shares
What Happened
Luke Evnin, a director of Werewolf Therapeutics, sold a total of 171,049 shares in three open‑market transactions between May 18–20, 2026, generating approximately $76,364 in gross proceeds. Breakdown by date: May 18 — 22,184 shares at a weighted avg $0.50 (≈ $11,092); May 19 — 62,970 shares at a weighted avg $0.45 (≈ $28,337); May 20 — 85,895 shares at a weighted avg $0.43 (≈ $36,935). These were sales (not purchases) and were effected pursuant to a Rule 10b5‑1 trading plan dated March 26, 2026.
Key Details
- Transaction dates & reported weighted averages:
- 2026-05-18: 22,184 shares, $0.50 (range $0.4931–$0.5059; see filing)
- 2026-05-19: 62,970 shares, $0.45 (range $0.4243–$0.50)
- 2026-05-20: 85,895 shares, $0.43 (range $0.40905–$0.4455)
- Total sold: 171,049 shares for ≈ $76,364.
- Shares held after each date (across affiliated entities listed in the filing):
- After 5/18: 1,104,312 shares
- After 5/19: 1,041,342 shares
- After 5/20: 955,447 shares
- Sales were executed by affiliated investment vehicles (AM LLC, BV 2014, BV 2014(B), AM BV2014, MPM OIF); Evnin is a member/manager of those entities and disclaims beneficial ownership except to the extent of his pecuniary interest (see filing).
- Notable: Transactions were made under a 10b5‑1 plan (dated March 26, 2026). Reported prices are weighted averages; the filing offers per‑trade price breakdowns on request. Filing dated May 20, 2026 — appears timely for trades occurring May 18–20.
Context
These were routine sales under a prearranged 10b5‑1 plan and were executed by investment entities affiliated with Evnin rather than direct open‑market sales from a personal brokerage account. Sales do not necessarily signal management views on company prospects; purchases generally carry more informational weight for investors.
Insider Transaction Report
Form 4
EVNIN LUKE
Director
Transactions
- Sale
Common Stock
[F1][F2][F3][F4][F5]2026-05-18$0.50/sh−22,184$11,092→ 1,104,312 total(indirect: See Footnotes) - Sale
Common Stock
[F1][F6][F7][F4][F8]2026-05-19$0.45/sh−62,970$28,337→ 1,041,342 total(indirect: See Footnotes) - Sale
Common Stock
[F1][F9][F10][F4][F11]2026-05-20$0.43/sh−85,895$36,935→ 955,447 total(indirect: See Footnotes)
Footnotes (11)
- [F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.40905 to $0.4455 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]The shares are held as follows: 102,366 by AM LLC, 646,324 by BV 2014, 43,107 by BV 2014(B), 22,244 by AM BV2014 and 141,406 by MPM OIF.
- [F2]The shares were sold as follows: 2,377 by MPM Asset Management LLC ("AM LLC"), 15,006 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,001 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 517 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 3,283 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4931 to $0.5059 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- [F5]The shares are held as follows: 118,316 by AM LLC, 747,025 by BV 2014, 49,823 by BV 2014(B), 25,710 by AM BV2014 and 163,438 by MPM OIF.
- [F6]The shares were sold as follows: 6,747 by AM LLC, 42,596 by BV 2014, 2,841 by BV 2014(B), 1,466 by AM BV2014 and 9,320 by MPM OIF.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4243 to $0.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The shares are held as follows: 111,569 by AM LLC, 704,429 by BV 2014, 46,982 by BV 2014(B), 24,244 by AM BV2014 and 154,118 by MPM OIF.
- [F9]The shares were sold as follows: 9,203 by AM LLC, 58,105 by BV 2014, 3,875 by BV 2014(B), 2,000 by AM BV2014 and 12,712 by MPM OIF.
Signature
/s/ Luke Evnin|2026-05-20